UnitedHealthcare Specialty Benefits Extends Coverage to ViziLite Plus, Zila's Oral Cancer Screening Product
June 19 2008 - 2:36PM
Business Wire
Zila, Inc. (NASDAQ:ZILA) today announced that UnitedHealthcare
Specialty Benefits (UHSB) began extending coverage for ViziLite�
Plus with TBlue�, Zila�s innovative screening device for the early
detection of oral abnormalities that could lead to cancer. "With
UnitedHealthcare Specialty Benefits making oral cancer screening
with ViziLite Plus a benefit, more than 21 million lives are now
covered," said David Bethune, chairman and chief executive officer
of Zila. "UHSB is joining a growing list of premier national
insurance plans that provide coverage for ViziLite Plus, including
Cigna, Humana, Guardian and Safeguard, as well as a number of
regional plans and self-insured employers. Over time, this new
coverage will encourage more screening for oral cancer, and, in
turn, enhance ViziLite Plus sales. We believe insurance providers
are extending coverage of ViziLite Plus because early cancer
detection leads to improved health outcomes for patients and lower
overall medical costs.� �Given that 25% of oral cancers occur in
people who do not smoke and have no other behavioral risk factors,
it is imperative that every adult be screened at least once a
year," said Mark Bride D.D.S., vice president, Medical Affairs at
Zila. "ViziLite Plus is a proven technology used by thousands of
dental offices across the United States.� About Oral Cancer and
ViziLite Plus One American dies every hour of oral cancer.
According to American Cancer Society data, nearly as many women
will be diagnosed with oral cancer as with cervical cancer this
year. The key to reducing the impact of this disease is early
detection. ViziLite Plus is an oral screening technology that
utilizes a chemiluminescent light source (ViziLite) and a patented
pharmaceutical-grade vital tissue dye (TBlue). The ViziLite Plus
exam takes only minutes and is totally painless and non-invasive.
Zila began marketing the product through its direct sales force in
the U.S. in February 2007, in Canada in November 2007, and launched
ViziLite Plus in Europe in May 2008. About UnitedHealthcare
Specialty Benefits UnitedHealthcare Specialty Benefits offers a
broad array of specialty benefits, including vision, dental, group
and voluntary insurance, worksite individual insurance and
non-insurance programs. UnitedHealthcare Specialty Benefits is a
business unit of OptumHealth, the health and wellness unit of
UnitedHealth Group, Inc. (NYSE:UNH). More information about
OptumHealth can be found at www.optumhealth.com/. About Zila, Inc.
Zila, Inc., is a fully integrated oral diagnostic company dedicated
to the prevention, detection and treatment of oral cancer and
periodontal disease. ViziLite� Plus, the company's flagship product
for the early detection of oral abnormalities that could lead to
cancer, is the first and only adjunctive medical device cleared by
the FDA for use in a population at increased risk for oral cancer.
In addition, Zila designs, manufactures and markets a suite of
proprietary products sold exclusively and directly to dental
professionals for periodontal disease, including the Rota-dent�
Professional Powered Brush, the Pro-Select� Platinum ultrasonic
scaler and a portfolio of oral pharmaceutical products for both
in-office and home-care use. This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based largely on
Zila's expectations or forecasts of future events, can be affected
by inaccurate assumptions and are subject to various business risks
and known and unknown uncertainties, a number of which are beyond
the Company's control. Therefore, actual results could differ
materially from the forward-looking statements contained herein. A
wide variety of factors could cause or contribute to such
differences and could adversely affect revenue, profitability, cash
flows and capital needs. There can be no assurance that the
forward-looking statements contained in this press release will, in
fact, transpire or prove to be accurate. For a more detailed
description of these and other cautionary factors that may affect
Zila's future results, please refer to Zila's Form 10-K for its
fiscal year ended July 31, 2007 and Form 10-Q for the quarter ended
April 30, 2008. For more information about the company and its
products, visit www.zila.com.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024